BMC Biotechnology, Journal Year: 2024, Volume and Issue: 24(1)
Published: Dec. 18, 2024
Language: Английский
Biomedicine & Pharmacotherapy, Journal Year: 2025, Volume and Issue: 183, P. 117782 - 117782
Published: Jan. 5, 2025
Language: Английский
Citations
1
Cuadernos de Educación y Desarrollo, Journal Year: 2025, Volume and Issue: 17(2), P. e7648 - e7648
Published: Feb. 27, 2025
O uso de nanopartículas como sistemas liberação controlada para o benznidazol tem demonstrado ser uma abordagem promissora otimizar tratamento da Doença Chagas. A modulação do fármaco por meio lipídicas e poliméricas oferece solução eficaz melhorar a biodisponibilidade reduzir os efeitos adversos frequentemente observados em tratamentos convencionais. mais fármaco, aliada à redução toxicidade hepática outros colaterais, torna as alternativa terapêutica viável pacientes com infecções crônicas, Além disso, direcionamento específico das células infectadas pelo Trypanosoma cruzi potencial aumentar eficácia tripanocida benznidazol. Estratégias "targeting", funcionalização ligantes específicos, anticorpos monoclonais, demonstraram grande sucesso seletividade minimizar sistêmicos. Isso representa um avanço significativo na busca terapias seguras eficazes, especialmente doenças endêmicas que exigem prolongados podem resultar devido administração medicamentos Apesar dos resultados promissores, aplicação clínica Chagas ainda enfrenta desafios técnicos, escalabilidade produção, estabilidade necessidade garantir segurança dessas terapias. No entanto, avanços nanotecnologia oferecem novas perspectivas desenvolvimento eficientes menos tóxicos, proporcionando no manejo e, possivelmente, outras infecciosas parasitárias. Mais pesquisas testes clínicos são necessários superar esses obstáculos tornar amplamente acessível crônicas.
Citations
0
International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: 662, P. 124476 - 124476
Published: July 18, 2024
Language: Английский
Citations
1
Therapeutic Delivery, Journal Year: 2024, Volume and Issue: 15(9), P. 699 - 716
Published: Aug. 5, 2024
Benznidazole (BNZ), a class-II drug, is the primary treatment for Chagas disease, but its low aqueous solubility presents challenges in formulation and efficacy. Nanosuspensions (NS) could potentially address these issues.
Language: Английский
Citations
1
Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(10), P. 1239 - 1239
Published: Sept. 24, 2024
Background: Neglected tropical diseases (NTDs), including leishmaniasis, trypanosomiasis, and schistosomiasis, impose a significant public health burden, especially in developing countries. Despite control efforts, treatment remains challenging due to drug resistance lack of effective therapies. Objective: This study aimed synthesize the current research on combination therapy phytochemical-loaded nanosystems, which have emerged as promising strategies enhance efficacy safety. Methods/Results: In present review, we conducted systematic search literature identified several phytochemicals that been employed this way, with notable reducing parasite load liver spleen cases visceral well lesion size cutaneous leishmaniasis. Furthermore, they synergistic effect against Trypanosoma brucei rhodesiense rhodesain; reduce inflammation, parasitic myocardium, cardiac hypertrophy, IL-15 production Chagas disease; affect both mature immature stages Schistosoma mansoni, resulting improved outcomes compared administration alone or conventional drugs. Moreover, majority combinations studied demonstrated enhanced solubility, efficacy, selectivity, increased immune response reduced cytotoxicity. Conclusions: These formulations appear offer therapeutic benefits, although further is required validate their clinical humans potential improve affected populations.
Language: Английский
Citations
1
Beilstein Journal of Nanotechnology, Journal Year: 2024, Volume and Issue: 15, P. 830 - 832
Published: July 8, 2024
Keywords: Aedes aegypti; Chagas disease; leishmaniasis; nanomedicine; nanotechnology; neglected tropical diseases; schistosomiasis
Language: Английский
Citations
0
Published: July 29, 2024
La enfermedad de Chagas es una parasitosis endémica América Latina. El agente etiológico del el parásito Trypanosoma cruzi, un protozoario hemoflagelado cuyo ciclo vida incluye hospedadores vertebrados (entre ellos, hombre) e invertebrados (insectos hematófagos triatominos). Existen sólo dos tratamientos farmacológicos utilizados contra la enfermedad: nifurtimox y benznidazol. Ambos presentan serios efectos adversos, siendo las más frecuentes, dermatitis, edema, fiebre, linfoadenopatía, dolor articular muscular, otros severos como púrpura trombocitopénica, agranulocitosis polineuropatías. hecho que drogas disponibles poseen probados tripanocidas alta eficacia en fase aguda, sugiere baja crónica podría deberse a problema biodistribución, esto es, imposibilidad alcanzar concentraciones efectivas nivel intracelular, donde se localiza mayormente forma predominante crónica. Por esta razón, numerosos autores han sugerido vehiculizar los fármacos antichagásicos vehículos farmacéuticos última generación (particularmente, nanovehículos) podrían ser gran utilidad para aumentar niveles fármaco tisular, mejorando dosificación, perfil seguridad, adherencia al tratamiento. objetivo tesis fue desarrollar nanovehículos alternativas terapéuticas superadoras tratamiento Chagas, optimizando seguridad actualmente disponibles. Se obtuvieron nanopartículas lipídicas poliméricas les realizó exhaustiva caracterización fisicoquímica, evaluación in vitro vivo modelo murino infección aguda. Si bien formulaciones no superadora libre ratón, encontró actividad tripanocida uno componentes resultar sinergismo con utilizan Chagas.
Citations
0
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(17), P. 9511 - 9511
Published: Sept. 1, 2024
Cyclodextrins are ring-shaped sugars used as additives in medications to improve solubility, stability, and sensory characteristics. Despite being widespread, Chagas disease is neglected because of the limitations available medications. This study aims review compounds formation inclusion complexes for treatment disease, analyzing incorporated advancements related studies. The databases consulted include Scielo, Scopus, ScienceDirect, PubMed, LILACS, Embase. keywords were “cyclodextrin AND disease” complex against Trypanosoma cruzi”. Additionally, a statistical analysis studies on over last five years was conducted, highlighting importance research this area. focused articles that emphasize how cyclodextrins can bioavailability, therapeutic action, toxicity, solubility Initially, 380 identified with keyword disease”; 356 excluded not directly topic, using Over years, total 13,075 found our literature analysis. also showed interest molecules derived from natural products vegetable oils. Research cyclodextrins, particularly context treatment, has advanced significantly, efficacy cyclodextrin indicating promising advances treatment.
Language: Английский
Citations
0
Drug Development and Industrial Pharmacy, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 39
Published: Sept. 11, 2024
This research aim to improve bioavailability and anti-hepatocellular carcinoma (HCC) efficacy of Ginsenoside Rg3 by modification with poly (lactic acid hydroxyacetic acid)-poly(ethylene glycol) (PLGA-PEG).
Language: Английский
Citations
0
BioNanoScience, Journal Year: 2024, Volume and Issue: 15(1)
Published: Dec. 2, 2024
Language: Английский
Citations
0